Arcus Biosciences (RCUS) Receivables - Net (2017 - 2025)
Arcus Biosciences (RCUS) posted quarterly Receivables - Net of $3.0 million for Q1 2025, down 98.68% year-over-year from $228.0 million in Q1 2024, and down 98.68% quarter-over-quarter from $228.0 million in Q4 2024.
Arcus Biosciences (RCUS) Receivables - Net (2017 - 2025) Analysis & Trends
Arcus Biosciences' Receivables - Net history runs 8 years deep, the most recent figure standing at $3.0 million for Q1 2025.
- In Q1 2025, Receivables - Net fell 98.68% year-over-year to $3.0 million; the TTM figure through Mar 2025 stood at $3.0 million (down 98.68% YoY), while the FY2024 annual figure was $228.0 million, up 7500.0% from the prior year.
- Receivables - Net for Q1 2025 stood at $3.0 million, down from $228.0 million in the prior quarter.
- The five-year high for Receivables - Net was $228.0 million in Q1 2024, with the low at $3.0 million in Q3 2023.
- The 5-year median for Receivables - Net is $4.1 million (2021), against an average of $56.7 million.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net surged 7500.0% in 2024, then tumbled 98.68% in 2025.
- Arcus Biosciences' Receivables - Net stood at $4.9 million in 2021, then fell by 18.37% to $4.0 million in 2022, then retreated by 25.0% to $3.0 million in 2023, then soared by 7500.0% to $228.0 million in 2024, then sank by 98.68% to $3.0 million in 2025.
- Business Quant data shows RCUS's Receivables - Net at $3.0 million in Q1 2025, $228.0 million in Q4 2024, and $228.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 228.00 Mn |
| Dec 31, 2024 | 228.00 Mn |
| Sep 30, 2024 | 228.00 Mn |
| Sep 30, 2024 | 228.00 Mn |
| Jun 30, 2024 | 228.00 Mn |
| Jun 30, 2024 | 228.00 Mn |
| Mar 31, 2024 | 228.00 Mn |
| Mar 31, 2024 | 228.00 Mn |
| Dec 31, 2023 | 3.00 Mn |
| Dec 31, 2023 | 3.00 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 4.00 Mn |
| Dec 31, 2022 | 4.00 Mn |